Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY6 | O43306 | 1/20 | 0.52 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.52 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.52 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.52 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.52 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.52 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.52 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.52 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.52 |
| ▸ | PNMT | P11086 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14925149 | 1.00 | ADCY6 (0.52) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Bromide SCHEMBL14917356 | 0.98 | ADCY6 (0.50) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Bromide SCHEMBL30406608 | 0.98 | ADCY6 (0.50) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Bromide SCHEMBL14917391 | 0.98 | ADCY6 (0.50) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL232676 | 0.81 | ADCY6 (0.77) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL30578821 | 0.81 | ADCY6 (0.77) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL30578817 | 0.81 | ADCY6 (0.77) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Bromide SCHEMBL3503361 | 0.79 | ADCY6 (0.74) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Hydrochloric Acid SCHEMBL3322965 | 0.79 | ADCY6 (0.74) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL19599676 | 0.79 | PNMT (0.37) | PNMTADRA2AADRA2BADRA2CASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| CN-110172051-A | IRE-1 alpha inhibitor | 复星弘创(苏州)医药科技有限公司 | 2019-08-27 | — | — | CN | disclosed |
| US-10357475-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-07-23 | — | — | US | disclosed |
| CN-107082770-B | IRE-1 alpha inhibitor | 复星弘创(苏州)医药科技有限公司 | 2019-04-23 | — | — | CN | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| CN-107082770-A | The alpha inhibitors of IRE 1 | 上海复星医药产业发展有限公司 | 2017-08-22 | — | — | CN | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| CN-103079558-A | IRE-1 alpha inhibitors | MANNKIND CORP | 2013-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | ADCY6 3596/4885ADCY3 3762/4885ADCY9 3554/4885 |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | ADCY6 3596/4885ADCY3 3762/4885ADCY9 3554/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | ADCY6 3712/4885ADCY3 3914/4885ADCY9 3636/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | ADCY6 3596/4885ADCY3 3762/4885ADCY9 3554/4885 |
| US-10357475-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | ADCY6 3712/4885ADCY3 3914/4885ADCY9 3636/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | ADCY6 3489/4885ADCY3 3721/4885ADCY9 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.